IDYA
Price
$27.17
Change
+$1.34 (+5.19%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
2.38B
67 days until earnings call
NUVL
Price
$80.89
Change
+$1.22 (+1.53%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
5.83B
62 days until earnings call
Interact to see
Advertisement

IDYA vs NUVL

Header iconIDYA vs NUVL Comparison
Open Charts IDYA vs NUVLBanner chart's image
IDEAYA Biosciences
Price$27.17
Change+$1.34 (+5.19%)
Volume$35.03K
Capitalization2.38B
Nuvalent
Price$80.89
Change+$1.22 (+1.53%)
Volume$12.23K
Capitalization5.83B
IDYA vs NUVL Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. NUVL commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and NUVL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (IDYA: $25.83 vs. NUVL: $79.67)
Brand notoriety: IDYA and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 145% vs. NUVL: 100%
Market capitalization -- IDYA: $2.38B vs. NUVL: $5.83B
IDYA [@Biotechnology] is valued at $2.38B. NUVL’s [@Biotechnology] market capitalization is $5.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both IDYA and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while NUVL’s TA Score has 6 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 4 bearish.
  • NUVL’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, both IDYA and NUVL are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а +3.61% price change this week, while NUVL (@Biotechnology) price change was +4.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

NUVL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($5.83B) has a higher market cap than IDYA($2.38B). NUVL YTD gains are higher at: 1.776 vs. IDYA (0.506). NUVL (-362.01M) and IDYA (-380.2M) have comparable annual earnings (EBITDA) . NUVL has more cash in the bank: 1.01B vs. IDYA (670M). IDYA has higher revenues than NUVL: IDYA (7M) vs NUVL (0).
IDYANUVLIDYA / NUVL
Capitalization2.38B5.83B41%
EBITDA-380.2M-362.01M105%
Gain YTD0.5061.77628%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash670M1.01B67%
Total Debt26.6MN/A-
FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
PROFIT vs RISK RATING
1..100
70
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
48
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYANUVL
RSI
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
77%
Bearish Trend 17 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTCSX31.720.35
+1.12%
Glenmede Small Cap Equity Adv
RNWAX86.450.18
+0.21%
American Funds New World R1
GGIDX13.15N/A
N/A
Goldman Sachs Global Infras Instl
MINVX29.24N/A
N/A
Madison Large Cap Y
JSEPX40.67N/A
N/A
JPMorgan Small Cap Equity R3

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with SYRE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.27%
SYRE - IDYA
61%
Loosely correlated
+1.07%
NRIX - IDYA
61%
Loosely correlated
-3.59%
CGON - IDYA
60%
Loosely correlated
+7.92%
IMNM - IDYA
60%
Loosely correlated
-4.39%
XENE - IDYA
58%
Loosely correlated
-0.49%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with CGON. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.16%
CGON - NUVL
55%
Loosely correlated
+7.92%
ABCZF - NUVL
51%
Loosely correlated
N/A
CRNX - NUVL
51%
Loosely correlated
-1.15%
RVMD - NUVL
50%
Loosely correlated
-2.06%
IDYA - NUVL
50%
Loosely correlated
+0.27%
More